Dulaglutide
GLP-1 Receptor Agonist — ALIMENTARY TRACT AND METABOLISM
Also known as: LY2189265, trulicity
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Dulaglutide is a drug in the GLP-1 Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2014. Its mechanism of action is classified as Glucagon-like Peptide-1 (GLP-1) Agonists. DrugCentral lists 1 molecular target, including GLP1R. Recorded indications include Diabetes mellitus type 2.
- Drug class: GLP-1 Receptor Agonist.
- Mechanism of action: Glucagon-like Peptide-1 (GLP-1) Agonists.
- Molecular targets: GLP1R (1 listed in DrugCentral).
- Indications: Diabetes mellitus type 2.
- ATC code: A10BJ05 (Glucagon-like peptide-1 (GLP-1) analogues).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Diabetes mellitus type 2
Mechanism & targets
| Mechanism of action (MoA) | Glucagon-like Peptide-1 (GLP-1) Agonists |
|---|---|
| Established pharmacologic class | GLP-1 Receptor Agonist |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Glucagon-like peptide 1 receptor | GLP1R | agonist | — |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2014-11-22 | EMA | — | — | |
| 2014-09-18 | FDA | — | ELI LILLY AND CO |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A10BJ05 | ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Glucagon-like peptide-1 (GLP-1) analogues |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Blood glucose increased | 1215.6 |
| Glycosylated haemoglobin increased | 995.9 |
| Injection site pain | 870.3 |
| Accidental underdose | 811.6 |
| Nausea | 750.4 |
| Extra dose administered | 559.0 |
| Diabetic ketoacidosis | 506.8 |
| Pancreatitis | 472.2 |
| Incorrect dose administered | 419.0 |
| Inappropriate schedule of product administration | 328.1 |
| Vomiting | 294.3 |
| Euglycaemic diabetic ketoacidosis | 268.7 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 923950-08-7 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Dulaglutide used for?
DrugCentral lists the following indications for Dulaglutide: Diabetes mellitus type 2.
How does Dulaglutide work?
Dulaglutide is classified as Glucagon-like Peptide-1 (GLP-1) Agonists; its molecular targets in DrugCentral include GLP1R (agonist).
When was Dulaglutide first approved?
Dulaglutide was first approved by the FDA in 2014.
What drug class does Dulaglutide belong to?
Dulaglutide is in the GLP-1 Receptor Agonist class.
Browse: all drugs starting with D · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4885 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2108027 — compound record and bioactivity
- DrugBank DB09045 — drug record
- FDA UNII WTT295HSY5 — substance identity
- DailyMed: FDA labels for Dulaglutide — current prescribing information (label search)
- UniProt P43220 (GLP1R) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.